Normally, our weekly look at what's going on within the health-care sectors involves a mixture of health-care conferences, FDA panel meetings and decisions, and a plethora of ...
Keep Reading →
March 24 - News
Big pharma loves Obamacare, right? After all, the main lobbying group for big pharma, the Pharmaceutical Researchers and Manufacturers of America, or PhRMA, spent $150 million...
Keep Reading →
March 23 - News
I'm not talking about NCAA basketball. March madness is here and everyone is filling out their brackets.
Keep Reading →
March 22 - News
The EU's decision to seize the bank accounts of ordinary Cypriot depositors was front and center again as concerns that the financial sector could come under tremendous pressure...
Keep Reading →
March 22 - News
ACADIA Pharmaceuticals Inc.
Keep Reading →
March 22 - News
Stock buybacks are generally considered a bullish signal on Wall Street.
Keep Reading →
March 22 - News
A lot of investors feel safe buying enormous conglomerates that dominate an industry, but few take notice of smaller players that dominate a niche.
Keep Reading →
March 22 - News
It’s almost here! Johnson & Johnson (NYSE:JNJ) is eagerly awaiting a decision on its type 2 diabetes drug Invokana (canagliflozin) by the end of the month.
Keep Reading →
March 22 - News
It’s no secret that the stock market has had a good run lately.
Keep Reading →
March 22 - News
Six to seven weeks after the end of each quarter, hedge funds and other major investors file 13Fs with the SEC to disclose many of their long equity positions as of the end of...
Keep Reading →
March 21 - Hedge Funds
The demand for drugs worldwide is expected to increase due to emerging markets abroad and more specifically, due to an influx of demand from the aging "Baby Boomers" domestically...
Keep Reading →
March 20 - News
There were cheers for joy when Abbott Laboratories (NYSE:ABT) announced that it would split itself into two entities -- separating the device and diagnostics businesses from ...
Keep Reading →
March 19 - News
Despite my recent obsession with Johnson & Johnson (NYSE:JNJ)'s restoration to health, I've long been a closet admirer of rival Pfizer Inc. (NYSE:PFE).
Keep Reading →
March 19 - News
Now more than ever, a comfortable retirement depends on secure, stable investments. Unfortunately, the right stocks for retirement won't just fall into your lap.
Keep Reading →
March 19 - News
Johnson & Johnson (NYSE:JNJ) was in 67 hedge funds' portfolio at the end of the fourth quarter of 2012. JNJ has experienced a decrease in hedge fund interest in recent months.
Keep Reading →
March 18 - Hedge Funds
What doesn't J&J produce? From pharmaceuticals to consumer care goods to medical devices, this major medical player has it all.
Keep Reading →
March 18 - News
The 30 stocks among the Dow Jones Industrial Average 2 Minute (Dow Jones Indices:.DJI) aren't just the leaders in their respective industries.
Keep Reading →
March 18 - News
Shares of Johnson & Johnson (NYSE:JNJ) have climbed 16% over the past five months and as of this writing, the stock is making new 52-week highs.
Keep Reading →
March 18 - News
Buying big pharma stocks isn't the only way you can invest in today's best-selling drugs without taking a gamble on a small, risky biotech.
Keep Reading →
March 18 - News
I still have two more companies to select, however, and I have been having a difficult time finding ones that meet my admittedly overly-strict criteria.
Keep Reading →
March 15 - News
With interest rates still sitting near record lows, investors looking for current income have been forced to move from fixed-income positions and into stocks to find yield.
Keep Reading →
March 14 - News
An Apple a day might not keep the doctor away, but the company's AppStore carries several solutions for tracking health care on the go -- and pharmaceutical companies continue...
Keep Reading →
March 14 - News
After the stomach-churning market drop of several years ago and the equally impressive climb back from 2009's lows, many investors are feeling a bit exhausted.
Keep Reading →
March 13 - News
May 2013 will mark the second annual National Mobility Awareness month.
Keep Reading →
March 13 - News
The $20 billion tax went into play on January 1.
Keep Reading →
March 13 - News
What doesn't Johnson & Johnson (NYSE:JNJ) produce? From pharmaceuticals to consumer care goods to medical devices, this major medical player has it all.
Keep Reading →
March 13 - News
Medical device makers Medtronic, Inc. (NYSE:MDT) and Stryker Corporation (NYSE:SYK) are at the top of an industry on the move.
Keep Reading →
March 12 - News
Investors have been left frustrated in these unstable times trying to find the best balance possible of security and growth.
Keep Reading →
March 12 - News
Recently there have been a wide variety of reports and opinions regarding where the stock market is heading next.
Keep Reading →
March 12 - News
The Motley Fool recently whittled down 1,700 public companies to name its list of The 25 Best Companies in America. Merck & Co., Inc.
Keep Reading →
March 12 - News
Now more than ever, a comfortable retirement depends on secure, stable investments. Unfortunately, the right stocks for retirement won't just fall into your lap.
Keep Reading →
March 11 - News
If you asked the average person on the street if America is overpopulated and the birth rate is too high, you'd likely receive "Yes" as your answer.
Keep Reading →
March 11 - News
Flip to the 2012 financial results for AbbVie Inc (NYSE:ABBV) and you'll see that its best-selling drug, Humira, brought in $9.27 billion in 2012, or 51% of the company's total...
Keep Reading →
March 11 - News
That's hardly the most shocking statistic of the obesity epidemic, America's most serious ongoing crisis.
Keep Reading →
March 10 - News
One of my favorite Warren Buffett quotes is that it’s far better to buy a wonderful company trading at a fair price than a fair company trading at a wonderful price. While...
Keep Reading →
March 10 - News
Gilead Sciences, Inc. (NASDAQ:GILD) is the world’s foremost biopharmaceutical company when it comes to combating deadly virus.
Keep Reading →
March 8 - News
Even after the automatic budget cuts known as "sequestration" went into effect last Friday, while Congress stood impotently on the sidelines as another deadline came and went, ...
Keep Reading →
March 8 - News
Investing in the health care sector isn't easy.
Keep Reading →
March 7 - News
Ultimately, that was the loss of those optimists. As value investors, we are not afraid of bad news as long as we get compensated by low valuations.
Keep Reading →
March 7 - News
Johnson & Johnson (NYSE:JNJ) may offer well-known personal care products such as Listerine and Neutrogena, but it also boasts an impressive portfolio of market-leading therapeutic...
Keep Reading →
March 7 - News
Now more than ever, a comfortable retirement depends on secure, stable investments. Unfortunately, the right stocks for retirement won't just fall into your lap.
Keep Reading →
March 7 - News
Eight months ago, Bayer and Johnson & Johnson (NYSE:JNJ) announced that the Food and Drug Administration had issued a complete response letter for their anticoagulant, Xarelto...
Keep Reading →
March 6 - News
Billionaire investor and Berkshire Hathaway founder Warren Buffett is a pupil of legendary investor Benjamin Graham.
Keep Reading →
March 6 - Hedge Funds
Tweedy Browne is one of the successful investment partnerships that was featured in Warren Buffett’s Graham-Doddsville Superinvestors article.
Keep Reading →
March 6 - Hedge Funds
Gilead Sciences, Inc. (NASDAQ:GILD)' sofosbuvir with Johnson & Johnson (NYSE:JNJ) and Medivir's simeprevir are a match made in heaven.
Keep Reading →
March 5 - News
Dendreon Corporation (NASDAQ:DNDN). investors have been on a perpetual roller coaster ride due to shifting expectations from Provenge.
Keep Reading →
March 5 - News
As I commented last week, cancer statistics are both staggering and disappointing.
Keep Reading →
March 5 - News
Short-selling is a vital component of healthy equity markets. Shorts may not be popular, but they help keep Mr. Market on his toes.
Keep Reading →
March 4 - News
Novo Nordisk A/S (ADR) (NYSE:NVO) recently got some bad news from the Food and Drug Administration: a request for additional information about a key insulin product.
Keep Reading →
March 1 - News
Though they’re underrated by the average investor, the hedge fund industry’s best managers are worth paying attention to.
Keep Reading →
February 27 - Hedge Funds
